Remote genetic counseling with optional digital tools for hereditary cancer testing
Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3)
This project will test telehealth and optional digital tools to deliver pre-test education and result disclosure for adults who qualify for hereditary cancer genetic testing.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 360 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Abramson Cancer Center at Penn Medicine Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT07471958 on ClinicalTrials.gov |
What this trial studies
The eREACH3 project observes how telehealth genetic counseling and optional digital tools are used as alternatives to the traditional two-visit genetic counseling model. Participants initially receive two remote genetic counseling visits and may be offered optional digital supports for education and result disclosure. The study will track uptake, patterns of tool use, and patient-reported cognitive, emotional, and behavioral outcomes at short-term and six-month follow-up. It will also measure provider time and identify barriers and facilitators to integrating these remote approaches into routine clinical care.
Who should consider this trial
Good fit: Adults (18+) who speak and understand English and who meet NCCN or other national criteria for germline genetic testing, or who seek genetic counseling based on personal or family cancer history, are ideal candidates.
Not a fit: Patients with uncorrected or uncompensated hearing, vision, or speech impairments, uncontrolled psychiatric illness, or severe cognitive deficits that prevent participation may not benefit from the telehealth and digital approaches.
Why it matters
Potential benefit: If successful, this could make genetic counseling more convenient and expand access by offering counseling at home with helpful digital supports.
How similar studies have performed: Previous research has shown telehealth genetic counseling can yield patient outcomes and satisfaction comparable to in-person care, though broad implementation using multiple optional digital tools is less well tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * Speak and understand English * Meet current National Comprehensive Cancer Network (NCCN) or other national guidelines for germline genetic testing or are interested in genetic counseling based on personal or family history of cancer. Patients with prior genetic testing are eligible if they meet criteria for updated testing, or if post-test genetic counseling services are requested. Exclusion Criteria: * Communication difficulties such as: * Uncorrected or uncompensated hearing and/or vision impairment. Patients who can successfully use clinical assistance devices are not excluded. * Uncorrected or uncompensated speech defects. Patients who can successfully use clinical assistance devices are not excluded. * Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks
Where this trial is running
Philadelphia, Pennsylvania
- Abramson Cancer Center at the University of Pennsylvania — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Angela Bradbury, MD — University of Pennsylvania
- Study coordinator: Angela Bradbury, MD
- Email: angela.bradbury@pennmedicine.upenn.edu
- Phone: 215-615-3341
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.